

Commercial/Healthcare Exchange Step Criteria
Effective: January 1, 2020

Step Therapy Name: Glaucoma Combinations

Step 1 Agent(s): Alphagan P, Combigan

Step 2 Agent(s): Betoptic S, Azopt, Simbrinza, Timoptic Ocudose, timolol maleate 0.5% ocudose

Required Medical Information:

1. Previous therapies tried/failed

Age Restrictions: N/A

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Exceptions for Stepped Medications

1. Patient has had a trial and failure of Alphagan P AND Combigan, defined as:
 - a. Failure to improve symptoms; **OR**
2. Patient has an intolerance or contraindication to Alphagan P AND Combigan, defined as (but not limited to):
 - a. Allergic reaction
 - b. Adverse drug reactions

References:

1. Product Information: BETOPTIC S ophthalmic suspension, betaxolol HCl ophthalmic suspension. Alcon Laboratories Inc (per FDA), Fort Worth, TX, 2016.
2. Product Information: AZOPT(R) ophthalmic suspension, brinzolamide 1% ophthalmic suspension. Alcon Laboratories, Inc (per FDA), Fort Worth, TX, 2015.
3. Product Information: SIMBRINZA(TM) ophthalmic suspension, brinzolamide 1% brimonidine tartrate 0.2% ophthalmic suspension. Alcon Laboratories, Inc. (per FDA), Fort Worth, TX, 2013.
4. Timoptic in Ocudose (timolol) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; April 2017.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/15/2019
2	Update	Added timolol maleate 0.5% ocudose to Step 2 agents	Step 2 agents	11/23/2020

